Dapagliflozin
Treatment for Chronic Kidney Disease Due To Diabetes Mellitus Type 1
Typical Dosage: 10mg once daily
Effectiveness
88%
Safety Score
65%
Clinical Trials
1
Participants
100K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
10mg once daily
Time to Effect
Months to years for renal/CV protection, weeks for glycemic/BP effects
Treatment Duration
Lifetime
Evidence Quality
MODERATENumber Needed to Treat (NNT)
20(Treat 20 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
30(Treat 30 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$5,500
Monitoring:$300
Side Effect Mgmt:$300
Total Annual:$6,100
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$60,000/QALY
QALYs Gained
0.6
Outcome-Based Costs
Cost per Responder
$8,133
Dapagliflozin Outcomes
for Chronic Kidney Disease Due To Diabetes Mellitus Type 1
Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+75%
Common Side Effects
Genital mycotic infections
+12%
Urinary tract infections
+8%
Hypotension
+4%
Euglycemic diabetic ketoacidosis (T1DM)
+3%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
1 completed trial for Dapagliflozin in Chronic Kidney Disease Due To Diabetes Mellitus Type 1
Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin.
NCT06374043COMPLETEDPHASE4
20 participants
INTERVENTIONAL
Almelo, Netherlands +1 more
Started: May 11, 2021